Pro zobrazení tohoto obsahu je třeba být přihlášen.
Author Archives for m.popovic@wemakemedia.cz
PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results
23 septembra, 2020 4:53 pm Leave your thoughtsMeeting: 2018 ASCO Annual Meeting Track: Breast Cancer—Local/Regional/Adjuvant Abstract number: 506 Authors: Helena Margaret Earl, Louise Hiller,...
Persephone Demonstrates Noninferiority of Shorter Duration Adjuvant Trastuzumab in HER2-Positive Breast Cancer
23 septembra, 2020 4:53 pm Leave your thoughtsJune 5, 2018 A 6-month duration of adjuvant trastuzumab with chemotherapy was found to be noninferior to 12 months...
TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score
23 septembra, 2020 4:53 pm Leave your thoughtsMeeting: 2018 ASCO Annual Meeting Track: Breast Cancer—Local/Regional/Adjuvant Abstract number: LBA1 Authors: Joseph A. Sparano, Robert James...
TAILORx: Many Women With Early Breast Cancer Can Avoid Chemotherapy
23 septembra, 2020 4:53 pm Leave your thoughtsJune 4, 2018 Endocrine therapy (ET) alone was noninferior to ET plus chemotherapy for women with estrogen receptor (ER)−positive,...
KARCINOM PRSU NA ASCO 2018
23 septembra, 2020 4:53 pm Leave your thoughtsNejvětší novinky prezentované na posledních konferencích ASCO se zpravidla netýkaly karcinomu prsu, ale jiných solidních nádorů, jako je maligní melanom, karcinom...
Comparison of different adjuvant therapy after radical surgery in early stage cervical carcinoma: A 3-arm randomized control study
23 septembra, 2020 4:53 pm Leave your thoughtsMeeting: 2018 ASCO Annual Meeting Track: Gynecologic Cancer Abstract number: 5529 Authors: He Huang, Li Yang, Yue...
ZoptEC: Phase III randomized controlled study comparing zoptarelin with doxorubicin as second line therapy for locally advanced, recurrent, or metastatic endometrial canceR
23 septembra, 2020 4:53 pm Leave your thoughtsMeeting: 2018 ASCO Annual Meeting Track: Gynecologic Cancer Abstract number: 5503 Authors: David S. Miller, Giovanni Scambia,...
Dendritic cell vaccine (DCVAC) with chemotherapy (ct) in patients (pts) with epithelial ovarian carcinoma (EOC) after primary debulking surgery (PDS): Interim analysis of a phase 2, open-label, randomized, multicenter trial
23 septembra, 2020 4:53 pm Leave your thoughtsMeeting: 2018 ASCO Annual Meeting Track: Gynecologic Cancer Abstract number: 5509 Authors: Lukas Rob, Peter Mallmann, Pawel...
A phase III randomized controlled trial of secondary surgical cytoreduction (SSC) followed by platinum-based combination chemotherapy (PBC), with or without bevacizumab (B) in platinum-sensitive, recurrent ovarian cancer (PSOC): A NRG Oncology/Gynecologic Oncology Group (GOG) study
23 septembra, 2020 4:53 pm Leave your thoughtsMeeting: 2018 ASCO Annual Meeting Track: Gynecologic Cancer Abstract number: 5501 Authors: Robert L. Coleman, Danielle Enserro,...
Comparison of survival between upfront primary debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomized trial: JCOG0602
23 septembra, 2020 4:53 pm Leave your thoughtsMeeting: 2018 ASCO Annual Meeting Track: Gynecologic Cancer Abstract number: 5500 Authors: Takashi Onda, Toyomi Satoh, Toshiaki...